The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2021Preclinical Testing of a Novel Tracer for Imaging Alpha-synuclein Aggregates
Study Rationale: In Parkinson's disease (PD), the protein alpha-synuclein is structurally altered such that clumps of alpha-synuclein accumulate in the brain. These aggregates impair the function of...
-
Target Advancement Program, 2021Exploring How a Chemical Produced by Intestinal Microbes Contributes to the Pathology and Progression of Parkinson's Disease
Study Rationale: Imbalances in the bacteria that inhabit the gut have been linked to the onset and progression of Parkinson’s disease (PD). However, the mechanisms by which an altered microbiome can...
-
Research Grant, 2021Hidden Sorrows of Covid-19: Impact of Stress on Parkinson’s Disease Progression
Study Rationale: People living with Parkinson’s disease (PD) are very sensitive to stress, which worsens motor symptoms (such as tremor) and leads to anxiety and depression. Studies in animals suggest...
-
Therapeutic Pipeline Program, 2021Wireless “Nanoelectrodes” as a Minimally Invasive Alternative to Conventional Deep Brain Stimulation
Study Rationale: Deep Brain Stimulation (DBS) has been used to ease motor symptoms in people with Parkinson’s disease (PD). This approach requires a surgical procedure to implant electrodes into the...
-
Expanding Biological Understanding of PD, 2021Dissecting the Role of GBA1 and LRRK2 in Regulating the Formation of Lewy Bodies
Study Rationale: A key hallmark of Parkinson’s disease (PD) is the accumulation of alpha-synuclein aggregates inside neurons. These aggregates are known as Lewy bodies (LBs). Although mutations in...
-
Research Grant, 2021Development of Alpha-synuclein and Tau Imaging Agents
Study Rationale: Accumulation of alpha-synuclein and tau protein aggregates are pathological hallmarks of Parkinson’s disease (PD) and Frontal Temporal Dementia (FTD), respectively. The appearance of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.